Majority of Hospitalized COVID Patients Are ‘Vaccinated’

August 2, 2021

https://www.brighteon.com/8d974c00-85a3-4cbb-a019-a29675f1c26d  News video Here  (Approx. 10 Min)

BREAKING! Majority of Hospitalized “COVID Patients” Are ‘VACCINATED’ | Dr. Jane Ruby

Published July 30, 2021

Dr. Jane Ruby joined Stew Peters to discuss the world’s most ‘vaccinated’ countries and how their recent spike in hospitalizations happens to be those who have recently been inoculated.

The data suggests that the shot is what’s making people ill, and that’s no surprise due to the recent ingredient revelations uncovered.

_________________

For more:

Category:

Activism, vaccines, Viruses

Comments Off on Majority of Hospitalized COVID Patients Are ‘Vaccinated’

Tickborne Illnesses in Finland

https://www.lymedisease.org/ticks-finland-2/

TOUCHED BY LYME: Tick-borne illnesses in Finland

April 28, 2021

Guest blogger C.M. Rubin interviews two European scientists about the prevalence of Lyme disease and other tick-borne infections in Finland.

The Global Search for Education: Finland — Ticks

by C M Rubin as featured in the Huffington Post

Lyme disease is caused by a bacterium transmitted to humans via a tick bite. The CDC (Center for Disease Control) claims that Lyme Borreliosis is the most common and fastest growing infectious illness in the United States. The disease can cause a variety of flu-like symptoms such as fever, achy joints, fatigue and headache. Additionally, Anaplasmosis/Ehrlichiosis, Babesiosis, Rocky Mountain Spotted Fever, Bartonella, Tularemia, and more recently, Borrelia Miyamotoi (a distant relative of Lyme Borreliosis) are other recognized tick-borne infectious diseases in the United States.

Experts have been unable to agree for decades on whether a case definition called chronic Lyme disease exists. Yet, some Lyme victims, even after taking the standard treatment of antibiotics, continue to suffer from long-term and often serious health problems for years after they first contract the disease. Does chronic Lyme disease exist, or is the condition which some patients experience an autoimmune or nervous system response triggered by the infection, or indeed is it a bit of both? These are some of the major questions researchers are trying to figure out as they take on the enormous challenges of identifying better Lyme diagnostic tools and treatment plans for what is becoming a growing global public health crisis.

Today in The Global Search for Education, I take a look at tick-borne illnesses in Finland. I am joined by Docent Jarmo Oksi, Finland’s leading researcher in the field of Lyme disease, who is based at the University of Turku in Finland. In addition, I welcome Markku Kuusi, Chief Medical Officer from Finland’s National Institute for Health and Welfare.

2013-04-25-cmrubinworldticks1400.jpg“The weakness of the Finnish surveillance system is that we don’t collect any clinical information on patients, we only get notifications from laboratories.” — Markku Kuusi
What is the annual incidence of Lyme disease in Finland and in Europe at large?Jarmo: Laboratory reports on Lyme Borreliosis cases (based on positive serology) have doubled in 10 years and are now about 1,500. The estimated number of Lyme Borreliosis infection cases is about four times this number — i.e. estimated incidence in Finland is 5,000-6,000 annually (population 5.5 million), which is about 100 per 100,000 inhabitants per year. However there are areas in the Southwestern Archipelago with incidence of 1000 per 100,000 inhabitants per year.

Markku: Based on the National Infectious Disease Register, the incidence of Lyme disease in Finland has been about 30/100,000 during the past few years. In terms of the annual incidence in other Nordic countries, in Norway it has been about 6/100,000 and in Denmark, 1 – 2/100,000. It is hard to believe that there is such a difference in actual incidence, so that is why I believe the diagnostic criteria are truly different. The weakness of the Finnish surveillance system is that we don’t collect any clinical information on patients, we only get notifications from laboratories; so it is difficult to say whether the symptoms of our cases really are compatible with Lyme Borreliosis.

Would you comment on the annual incidence of any of the other tick-borne illnesses which are endemic in Finland in addition to Lyme.

Markku: Tick-borne Encephalitis (TBE) is another important tick-borne disease in Finland. The incidence has been particularly high on Aland Island and therefore TBE vaccination is included in the national immunization program. Before the vaccination program, the annual incidence was up to 100/100,000 population. Now it has decreased substantially. It seems that in other parts of Finland (apart from Aland Island), the incidence is increasing, and therefore other areas may also be included in the immunization program in the near future (for example, the Archipelago around the city of Turku).

Do you believe that chronic Lyme disease exists or that it is a misnomer for other diseases triggered by Lyme disease?

Markku: This is a difficult question. I think it is clear that some patients have a prolonged course of the disease which may last several months. The most experienced clinicians in Finland think that a continuing Borrelia infection is possible if the patient has not received adequate treatment for the illness, resulting in disseminated infection. Even after adequate treatment, some patients have symptoms due to immunological mechanisms, but it is very hard to say whether these symptoms are related to Borrelia infection or to some other causes.

2013-04-25-cmrubinworldlabra_182.JPG_3420500.jpg“The most experienced clinicians in Finland think that a continuing Borrelia infection is possible if the patient has not received adequate treatment for the illness, resulting in disseminated infection.”— Markku Kuusi
If you believe in chronic Lyme disease, what do you believe are the most effective ways to treat it?Jarmo: If you mean chronic infection, I think that this entity after standard antibiotic therapy is very very seldom (I see about one case in five years). However, if detected –e.g. with cultivation or PCR (the most specific way to detect), the treatment I give is individual antibiotic treatment — maybe double the length compared to the initial treatment.

What do you believe is the most effective way to treat symptoms triggered by the infection, e.g. chronic auto-immune reaction?

Jarmo: During the first months I wait for gradual improvement. If there is no improvement after six to 12 months, I then start low-dose corticosteroid treatment for a certain subset of patients. Some other subsets may get help from, for example, amitriptyline, which raises the threshold for pain sensation.

What tests currently available to the general public, other than the Western Blot test, do you believe provide a better degree of certainty?

Jarmo: PCR (and culture) are useful in some situations (culture only in research settings), but even PCR is not sensitive enough to detect all cases — e.g. in CSF (cerebrospinal fluid) of neuroborreliosis cases. Besides Western Blots, ELISA tests based on C6 peptide are generally good as confirmatory tests.

2013-04-25-cmrubinworld_P6Q5372.JPG_198500.jpg“We are currently enrolling patients into a study on neuroborreliosis: comparison of IV Ceftriaxone for 3 weeks vs. oral Doximycin for 4 weeks. Hopefully this study will give us new knowledge on markers of how to identify patients with reactive symptomatology triggered by Lyme neuroborreliosis.”— Jarmo Oksi
Are you aware of any other promising tests in development?Markku: Last year, a Finnish group reviewed the diagnostic tests in our country. It is my understanding that right now there are not unfortunately any new reliable tests available. So we shall have to wait awhile for them.

To what research do you believe scientists around the world must give priority in order to overcome the challenges the public faces with finding a cure for Lyme disease?

Markku: I think it is important to better understand the mechanism behind the sequelae of acute borreliosis. Therefore, we need more research on the immunology of the disease. In other words, how does the bacteria actually cause joint symptoms or neurologic symptoms. I think this will help us to develop better diagnostic tests and hopefully better drugs. I believe antibiotics are not the only solution.

What is the focus of your research and how does it relate to the challenges of identification and cure of Lyme disease and diseases triggered by Lyme?

Jarmo: We are currently enrolling patients into a study on neuroborreliosis: comparison of IV Ceftriaxone for three weeks vs. oral Doximycin for four weeks. Hopefully this study (with control CSF specimens) and long follow-ups of patients also will give us new knowledge on markers of how to identify patients with reactive symptomatology triggered by Lyme neuroborreliosis.

How can technology help us find a cure for Lyme disease faster?

Markku: This is not really a field in which I am knowledgeable, but I believe that better molecular and immunological methods may give possibilities for new diagnostics and for the development of new drugs. What I really hope is that there will be better and more specific laboratory tests for Lyme Borreliosis in the future. I think that one of the key issues is to harmonize the laboratory methods so that we can get a better understanding of the epidemiology of Lyme disease in Finland.

C M Rubin is a child and family health and education advocate.  She is the author of a number of award winning books as well as the widely read online series THE GLOBAL SEARCH FOR EDUCATION.

Follow C. M. Rubin on Twitter: www.twitter.com/@cmrubinworld

___________________

**Comment**

I disagree with two tenets in this paper:

  • Chronic Lyme is rare.  I personally, as well as my husband, and most I deal with have improved immensely or even reached remission with lengthy treatment utilizing numerous antimicrobials and other modalities.  As they say, “The proof is in the pudding.”  Lyme spirochetes have been found in the autopsied brain despite treatment.  There are also extensive global research showing the persistence of the organism in 700 peer-reviewed papers (as well as coinfections that often come with Lyme): Peer-Reviewed Evidence of Persistence of Lyme:MSIDS copy  Please keep in mind that everything is rigged against reporting chronic infection. Globally, doctors work under the CDC/IDSA’s myopic focus on the acute phase and frank denial of persistent infection.  It doesn’t surprise me at all that a Finnish researcher also cow-tows to this thinking.  It’s rampant.
  • That we need yet more research on the acute phase of Lyme.  Frankly, that’s about all we have.  We desperately need researchers to quit myopically focusing on this phase of the illness and study the thousands upon thousands with chronic/persistent symptoms who often do to not test positive on the abysmal CDC 2-tiered testing, which is rigged to not pick up chronic infection, and do not have the “classic” EM rash.  These two variables have kept the sickest patients from being studied.

Category:

Anaplasmosis, Babesia, Bartonella, Borrelia Miyamotoi (Relapsing Fever Group), Lyme, Rocky Mountain Spotted Fever, Ticks, Tularemia

Comments Off on Tickborne Illnesses in Finland

Assessing the Need for Multiplex & Multifunctiounal Tick-borne Disease Test in Routine Clinical Lab Samples From Lyme Disease & Febrile Patients With History of Tick Bite

https://pubmed.ncbi.nlm.nih.gov/33803065/

Assessing the Need for Multiplex and Multifunctional Tick-Borne Disease Test in Routine Clinical Laboratory Samples from Lyme Disease and Febrile Patients with a History of a Tick Bite

Kunal Garg 1, T Sakari Jokiranta 2, Sanna Filén 2, Leona Gilbert 1
Affiliations expand

Free PMC article

Abstract

Human polymicrobial infections in tick-borne disease (TBD) patients is an emerging public health theme. However, the requirement for holistic TBD tests in routine clinical laboratories is ambiguous. TICKPLEX® PLUS is a holistic TBD test utilized herein to assess the need for multiplex and multifunctional diagnostic tools in a routine clinical laboratory. The study involved 150 specimens categorized into Lyme disease (LD)-positive (n = 48), LD-negative (n = 30), and febrile patients from whom borrelia serology was requested (n = 72, later “febrile patients”) based on reference test results from United Medix, Finland. Reference tests from DiaSorin, Immunetics, and Mikrogen Diagnostik followed the two-tier LD testing system.

  • A comparison between the reference tests and TICKPLEX® PLUS produced 86%, 88%, and 87% positive, negative, and overall agreement, respectively.
  • Additionally, up to 15% of LD and 11% of febrile patients responded to TBD related coinfections and opportunistic microbes.

The results demonstrated that one (TICKPLEX® PLUS) test can aid in a LD diagnosis instead of four tests. Moreover, TBD is not limited to just LD, as the specimens produced immune responses to several TBD microbes. Lastly, the study indicated that the screening of febrile patients for TBDs could be a missed opportunity at reducing unreported patient cases.

Conflict of interest statement

K.G and L.G. have a financial and business interest in Tezted Ltd. Further, S.J and S.F do not have commercial or financial relationships that could be construed as potential conflicts of interest. The funding source mentioned in the Funding and Acknowledgements section and Tezted Ltd. had no role in the experimental design, reporting of the results, or the decision to publish.

__________________
For more:

Category:

Lyme, research, Testing

Comments Off on Assessing the Need for Multiplex & Multifunctiounal Tick-borne Disease Test in Routine Clinical Lab Samples From Lyme Disease & Febrile Patients With History of Tick Bite

AAP is ‘CDC Junior’, Funded by Pfizer, It Predictably Recommends COVID Shots for Kids

July 29, 2021

download

Funded by 

2000px-Pfizer_logo.svg_

The American Academy of Pediatrics (AAP) despite data showing children are nearly impervious to COVID, and that it can be effectively treated, updated its “guidance” on children and schools on July 18, 2021.  They are recommending all students, teachers, and staff wear masks while indoors, despite much evidence masks do not work and are actually harmful.  Further, the AAP is recommending that children 12-18 get “vaccinated” despite the very real risk of myocarditis and numerous other adverse events.

Injecting children with this experimental gene therapy, who rarely get COVID or transmit it, have more than a 99.9% chance of surviving, and that there are effective treatments for is the height of insanity.

Martin Makary MD, MPH,Editor-in-Chief, MedPage Today states:

THINK TWICE BEFORE GIVING THE COVID VAX TO HEALTHY KIDS

— BASED ON THE DATA TO DATE, THERE’S NO COMPELLING CASE FOR IT RIGHT NOW

LARGE U.K. STUDY, the most comprehensive data on the topic backs up clinical reports that show children and teens are less likely to be hospitalized or face severe effects from the “virus.”

This is where citizen journalists show the ugly truth behind the AAP’s recommendations: the only “vaccine” authorized for emergency use (EUA) is Pfizer.

The “boots on the ground” arm of the AAP, The AAP CATCH Program is:

funded by Pfizer. 

It appears the AAP is taking lessons from the CDC.

The CDC Foundation, an arm of the CDC, gets millions from private donors, while obtaining BILLIONS in tax payer dollars, proving they are not a neutral government agency that can be trusted. The NIH, another governmental agency, developed and owns the patent on the stabilized spike protein being used in all the COVID injections, and owns half of Moderna, another COVID injection manufacturer.

Twitter users shared screen shots and archived links proving Pfizer funds the AAP CATCH program. Two days later on July 23, the AAP removed ALL mention of Pfizer from that page.

Pfizer gave the AAP at least $50,000 in the first two quarters of 2020 according to the company’s own documents, but these monies are only what the company openly-admits to. The AAP is almost entirely funded by pharmaceutical companies, including Johnson and Johnson (J&J), Merck, and Sanofi.

How can this organization or any government agency be trusted at all to make sound recommendations for children?

Do not allow conflict-riddled organizations to make health decisions for you or your child.

These proven conflicts make our public health ‘authorities’ proclamations fall on deaf ears. They continually manipulate data for their own nefarious ends, and hide data that is inconvenient for them. Even CDC researchers have exposed the agency’s blatant corruption.

For more:

Category:

Activism, vaccines, Viruses

Comments Off on AAP is ‘CDC Junior’, Funded by Pfizer, It Predictably Recommends COVID Shots for Kids

Corruption in ‘Public Health’ and Beyond is Rampant, Warns Fed Turned Whistleblower & How They Pull in Millions From Licensing Deals, Including COVID-Related Technologies

**UPDATE March, 2022**

A study released Monday found 95% — 19 of the 20 members — of the U.S. government-run committee responsible for establishing dietary guidelines for Americans have one or more conflicts of interest (COIs) with industry actors in Big Food, Big Ag and Big Pharma.

According to this article, these guidelines are used by policy makers, health care providers, nutrition educators, and federal nutrition program operators – including those responsible for school lunch programs. This amounts to nearly $100 BILLION annually.

https://thenewamerican.com/corruption-in-public-health-and-beyond-is-rampant-warns-fed-turned-whistleblower/?mc_cid=f1853607d3  Video Here

Corruption in ‘Public Health’ and Beyond is Rampant, Warns Fed Turned Whistleblower

 by Alex Newman 
Corruption and criminality is rampant all through the federal government, former federal official turned whistleblower Nathan Gjovik tells The New American magazine’s Alex Newman. The whistleblower, who worked for four different federal agencies and departments before exposing the lawlessness in his book “Netherworld: Reflections on Working for the U.S. Government,” says he observed all sorts of corruption while serving as a commissioned officer in the U.S. Public Health Service. Instead of dealing with the corruption, the federal government retaliated against him in various ways.

DISCLAIMER: Views and opinions expressed in this interview are solely those of the interviewee and do not necessarily represent those of The New American. TNA is not responsible for, and does not verify the accuracy of, any information presented.

__________________

https://childrenshealthdefense.org/defender/regulatory-corruption-cdc-nih-millions-licensing-deals-covid-technologies/

07/28/21

‘Recipes for Regulatory Corruption’: How CDC, NIH Pull in Millions From Licensing Deals, Including COVID-Related Technologies

Aggregated data for fiscal year 2020 show the NIH and CDC collected a combined $63.4 million in royalty revenues under a business model that allows the NIH to grant technology licenses to the private sector.

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It’s free.

With 27 different institutes and centers housed under the National Institutes of Health (NIH) umbrella — including the National Institute for Allergy and Infectious Diseases (NIAID)  — NIH is the largest biomedical research agency in the world.

Operating under the U.S. Department of Health and Human Services (HHS), NIH currently wields a hefty annual budget of nearly $42 billion.

Within NIH, the Office of Technology Transfer (OTT) plays a “strategic role” in supporting patenting and licensing for inventions that emerge from laboratories at the NIH and also Centers for Disease Control and Prevention (CDC).

In a win-win business model, the NIH routinely grants technology licenses (both exclusive and non-exclusive) to the private sector for use or commercialization of its inventions, with those licenses then driving billions of dollars in royalties back into NIH coffers.

In fiscal year (FY) 2020 alone — October 2019 through September 2020 — aggregated data for NIH and CDC show the agencies collected a neat $63.4 million in royalty revenues.  (See link for article)

___________________

**Comment**

There is no way on earth public health ‘authorities’ can make unbiased decisions with this kind of money changing hands.

  • The article points out that Universities also receive royalties (disingenuously classified as “federal compensation” rather than “outside income”) when they market patented technologies, yet taxpayers continue paying universities for research.
  • Many NIH scientists routinely fail to disclose royalty payments – one of whom is Fauci, the highest paid federal employee.
  • Evidently the NIH doesn’t report which patents are licensed or release data that would help the public evaluate how licensing affects access to resulting drugs.
  • Public information was lacking in the OTT’s FY2020 annual report, yet had $63.4 million in FY2020 royalty revenues, with a significant 20% uptick in invention disclosures (invention disclosures are the first step in the patenting process) and 47% more patent applications compared to the previous year. NIH executed more licenses in FY2020 (n=359) than in any prior fiscal year dating back to 1985.
  • CDC’s webpage listing technologies available for licensing (and, therefore, with the potential to generate royalties) has not been updated since May, 2020, when it had about 60 technologies, many related to diagnostics or vaccine development.  There will be considerably more once it’s updated.
  • 66% of CDC grant funds in 2020 were COVID-related.
  • The Biden administration has requested a 21% NIH budget increase – to $51 billion.
  • Most frightening of all is the creation of a new NIH which will merge national security with health security modeled after DARPA.  (Hopefully you can see where this is going, if not, read this).

Please look at the shark feeding frenzy resulting from NIAID-developed SARS-CoV-2 spike proteins and plasmids (molecules encoding the spike proteins) to spur development of COVID-19 diagnostics, treatments and vaccines:

  • Ninety-six agreements with 75 academic organizations, nonprofit entities, government agencies, international organizations and other entities to furnish NIAID spike proteins or plasmids for research projects (called “material transfer agreements”)

  • Twenty-one licenses negotiated with biotechnology or pharmaceutical companies, mostly for SARS-CoV-2 vaccine development — these licenses pertain to “most of the vaccines in advanced clinical trials and several currently in use around the world” (notably, the Moderna mRNA-1273 vaccine that received Emergency Use Authorization in Dec. 2020)

  • An additional 16 agreements to collaborate on research, including four clinical trial agreements for SARS-CoV-2 vaccines  Source

It appears that COVID is good for government business, but not so good for public health.

The article finishes by pointing out the irony that the highly censored COVID treatments, which are cheap, safe, and effective are not what “royalty-hungry” scientists are interested in.  In the words of Columbia University’s Dr. Ian Lipkin, they prefer novel treatments that are “sexy and new and patentable.”

These treatments also don’t further the global control agenda behind the NIH’s new DARPA-like agency.

For more:

Category:

Activism, vaccines, Viruses

Comments Off on Corruption in ‘Public Health’ and Beyond is Rampant, Warns Fed Turned Whistleblower & How They Pull in Millions From Licensing Deals, Including COVID-Related Technologies